KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2025)

Sarepta Therapeutics (SRPT) has 10 years of Finished Goods data on record, last reported at $64.8 million in Q3 2025.

  • For Q3 2025, Finished Goods fell 16.9% year-over-year to $64.8 million; the TTM value through Sep 2025 reached $64.8 million, down 16.9%, while the annual FY2024 figure was $47.2 million, 23.62% down from the prior year.
  • Finished Goods reached $64.8 million in Q3 2025 per SRPT's latest filing, down from $71.0 million in the prior quarter.
  • Across five years, Finished Goods topped out at $78.0 million in Q3 2024 and bottomed at $26.7 million in Q4 2021.
  • Average Finished Goods over 5 years is $46.4 million, with a median of $47.2 million recorded in 2024.
  • Peak YoY movement for Finished Goods: surged 713.44% in 2021, then dropped 23.62% in 2024.
  • A 5-year view of Finished Goods shows it stood at $26.7 million in 2021, then skyrocketed by 42.78% to $38.1 million in 2022, then surged by 62.02% to $61.8 million in 2023, then decreased by 23.62% to $47.2 million in 2024, then skyrocketed by 37.27% to $64.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $64.8 million in Q3 2025, $71.0 million in Q2 2025, and $61.4 million in Q1 2025.